Sichuan Kelun-Biotech
Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.
Sacituzumab tirumotecan (first TROP2 ADC approved in China), MK-3120 Nectin-4 ADC, and a broad ADC platform partnered with Merck (up to $9.3B).
Pages like this
not linked directly; found by shared links- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab tirumotecan, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialASCENT-03
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast02
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialASCENT
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast05
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- PersonXichun Hu
Shares Sacituzumab tirumotecan, Triple-negative breast cancer (TNBC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares Sacituzumab tirumotecan, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- IdeaEfflux-agnostic therapy for mesenchymal TNBC
Shares Sacituzumab tirumotecan, Triple-negative breast cancer (TNBC).